Cannabics Pharmaceuticals
3 Bethesda Metro Center, #700
Bethesda
Maryland
20814
United States
Tel: 877-424-2429
Website: http://www.cannabics.com/
Email: info@cannabics.com
About Cannabics Pharmaceuticals
Cannabics Pharmaceuticals is dedicated to the development of Personalized Anti-Cancer treatments.YEAR FOUNDED:
2012
LEADERSHIP:
Founder and CEO: Itamar Borochov
FOLLOW CANNABICS:
Tweets by Cannabics
84 articles with Cannabics Pharmaceuticals
-
Cannabics Pharmaceuticals to Initiate in-vivo Dose Response Study on Proprietary Colorectal Cancer Drug Candidate RCC-33
3/31/2021
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, announced today it is initiating a Dose Response in-vivo Study in mice; results to be included as part of the Product Package to be submitted to the U.S. Food and Drug Administration
-
Cannabics Pharmaceuticals' Drug Candidate RCC-33 Prolongs Survival Rate in Mice Inoculated with Human Colorectal Cancer Cells
3/17/2021
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, released today the concluding results of its in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 in prolonging survival rate in mice
-
Cannabics Pharmaceuticals' in-vivo Tumor Inhibitory Effect Study Concludes with a Statistical Significance of p ≤ 0.016
2/17/2021
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, further clarifies with regards to the final study results released on February 16, 2021 ,
-
Cannabics Pharmaceuticals' in-vivo Study concludes with a 33% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer
2/16/2021
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, has just released the final results of its in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 for the treatment of colorectal cancer in nude-mice.
-
Cannabics Pharmaceutical's Interim in-vivo Study Results Show a 27% Lower Tumor Volume in Mice Treated with Company's Proprietary Drug Candidate for Colorectal Cancer
2/3/2021
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicines, announced today that it has obtained interim results for its ongoing in-vivo study evaluating the efficacy of the company's proprietary drug candidate RCC-33 for colorectal cance
-
Cannabics Pharmaceuticals Initiates In-Vivo Animal Studies for FDA Pre-IND Meeting Package
12/21/2020
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, announced today that it has initiated a series of proof of concept (POC), in-vivo , animal model studies to test its drug candidate RCC-33 on mice tr
-
Cannabics Pharmaceuticals Founds Digestix Bioscience Inc., a Subsidiary for Treatment of Precancerous and Early Stage Neoplastic Local Tumors
11/16/2020
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, announced today that it has established a subsidiary, Digestix Bioscience Inc., a company dedicated to the development of medical devices and pharmace
-
Cannabics Concludes a Pre-Clinical Study on Human Biopsies in Preparation for FDA pre-IND Meeting Request on Colorectal Cancer Drug Candidate RCC-33
11/9/2020
Cannabics Pharmaceuticals Inc., a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, announced that it has completed a pre-clinical study using its proprietary and novel RCC-33 formulation on human biopsies, obtained under a Helsinki Committee approved protocol.
-
Cannabics Pharmaceuticals receives "Intention to Grant a European Patent" notice for its System and Method for High Throughput Screening of Cancer Cells patent application
10/27/2020
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, announced today that it has been informed by the European Patent Office that the examining division intends to grant the company a European Patent for
-
Cannabics Pharmaceuticals Prepares to Submit the FDA with a pre-IND Meeting Request for its Proprietary Colon Cancer Drug Candidate, CANNABICS™ RCC-33
10/21/2020
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, announced today that it has signed an agreement with a leading clinical quality and validation processes consultancy to oversee the preparation and submissi
-
Cannabics Pharmaceuticals to Establish a Division for its Antitumor Drug Candidate RCC-33
8/20/2020
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it is establishing a dedicated division for the development of its Antitumor Drug Candidate RCC-33 for the treatment of colorectal cancer.
-
Cannabics Pharmaceuticals Appoints Dr. Dana Ben-Ami Shor (MD), Gastroenterologist, to its Scientific Board of Advisors
8/5/2020
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has appointed Dr. Dana Ben-Ami Shor to its Scientific Board of Advisors.
-
Cannabics Pharmaceuticals Initiates Penetration for Its Cannabinoid Diagnostic Platform Into European Markets
7/14/2020
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has initiated activities to penetrate European markets in order to offer a test based on its diagnostic platform to patients who suffer from cancer and a
-
Cannabics Pharmaceuticals Appoints Dr. Erez Scapa, MD to its Scientific Board of Advisors
6/16/2020
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has appointed Dr. Erez Scapa to its Scientific Board of Advisors.
-
Cannabics Pharmaceuticals and Cannomed Collaborate to Develop Cannabis Strains Targeting Cancers
6/10/2020
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has signed a Memorandum Of Understanding with Cannomed Medical Cannabis Industries Ltd. (TASE: CNMD), to develop cannabis cultivars targeted to treat c
-
Cannabics Pharmaceuticals to Capitalize on Israel's Final Approval for the Export of Medical Cannabis
5/26/2020
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that the Israeli government has granted final approval for the export of medi
-
Cannabics Pharmaceuticals Files Provisional Patent on Composition and Method for Treating Colon Cancer With Cannabinoids
5/6/2020
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has filed a Provisional Patent Application with the US Patent & Trademark Office (USPTO) entitled "Composition and Method for Treating Colon Cancer with
-
Cannabics Pharmaceuticals Appoints Prof. Zamir Halpern to Its Scientific Board of Advisors
4/27/2020
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has appointed Prof. Zamir Halpern to its Scientific Board of Advisors.
-
Cannabics Pharmaceuticals Develops Novel Cannabis Formulation for the Treatment of Colon Cancer
4/13/2020
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has completed its preclinical development of a novel formulation containing cannabinoids which have demonstrated anti-tumor properties in studies held at the company's High Throughput Screening (HTS) research facility in Israel, which were focused on gastrointestinal cancers.
-
Cannabics Pharmaceuticals Offers Its High Throughput Screening (HTS) Platform to the Israeli Health Authorities for SARS-CoV-2 Research
3/18/2020
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it is offering its High Throughput Screening (HTS) facility , in order to assist with the Israeli national effort in researching and containing SARS-CoV